Australasian Journal of Dermatology最新文献

{"title":"Sun Safety Policy Implementation in Australian Primary Schools.","authors":"Katherine Lissner, Annabel Stevenson","doi":"10.1111/ajd.14461","DOIUrl":"https://doi.org/10.1111/ajd.14461","url":null,"abstract":"<p><strong>Background/objectives: </strong>Current SunSmart policy in Australia is implemented and reviewed by the Cancer Council using self-reported survey data.</p><p><strong>Methods: </strong>Researchers conducted an external assessment of the implementation of sun safety policies in Australian primary schools by conducting a national survey with questions constructed based on the SunSmart policy. Multivariable binary logistic regressions were performed to understand the relationships between the various sun-safety activities and school characteristics.</p><p><strong>Results: </strong>We hypothesised that schools with a higher ultraviolet (UV) exposure rating would perform better due to higher perceived risk. This was true for year-round uniform policy and presence of outdoor sails. Use of sunscreen in Australian schools remains inadequate. Students at more advantaged schools were 2.1 times more likely to use sunscreen, potentially demonstrating a relationship between financial access or awareness, providing an avenue for future funding decisions. Use of sun-protective eyewear remains insufficient, with only 11.1% of schools encouraging use, but Catholic school students are twice as likely to wear sunglasses. Schools in extreme UV areas had the lowest odds ratio of sunglasses use, highlighting a clear target for future intervention. Other important differences in school type were found, including that independent school students have a 58% lower likelihood of wearing SunSmart adherent uniforms.</p><p><strong>Conclusions: </strong>We found statistically significant inequalities in sun safety behaviours in different school types in Australia, providing utility for future funding and policy decisions.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Squamous Cell Carcinoma Clinically Thought to be Arising From Bursa of Knee Joint","authors":"Shoichi Sakamoto,&nbsp;Yuki Yamamoto,&nbsp;Michihiro Takiwaki,&nbsp;Yumi Nakantani,&nbsp;Seiji Kanno,&nbsp;Yoshimasa Mera,&nbsp;Masazumi Tanigami,&nbsp;Yusuke Inada,&nbsp;Yutaka Inaba,&nbsp;Kayo Kunimoto,&nbsp;Hiroshi Yamada,&nbsp;Yoshifumi Iwahashi,&nbsp;Shin-ichi Murata,&nbsp;Masatoshi Jinnin","doi":"10.1111/ajd.14430","DOIUrl":"10.1111/ajd.14430","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 3","pages":"175-177"},"PeriodicalIF":2.2,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Photodynamic Treatment of a Pigmented Nodular BCC Using a Biphasic Activation Protocol","authors":"Robert Stephens,&nbsp;Antony Johnston,&nbsp;Rolf B. Saager,&nbsp;Chris D. Anderson","doi":"10.1111/ajd.14458","DOIUrl":"10.1111/ajd.14458","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 3","pages":"e179-e181"},"PeriodicalIF":2.2,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating Inverse Lichen Planus With Upadacitinib: A Case Study","authors":"Yang Ying,&nbsp;Huang Jia-Min,&nbsp;Sun Zhao-Jun","doi":"10.1111/ajd.14459","DOIUrl":"10.1111/ajd.14459","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 3","pages":"e182-e184"},"PeriodicalIF":2.2,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Intensity Focused Ultrasound—Application, Effects and Complications","authors":"Natalia Welc,&nbsp;Michał Owczarek,&nbsp;Magdalena Jałowska,&nbsp;Aleksandra Dańczak-Pazdrowska","doi":"10.1111/ajd.14454","DOIUrl":"10.1111/ajd.14454","url":null,"abstract":"<div>\u0000 \u0000 <p>The HIFU method (high-intensity focused ultrasound) has gained great popularity in aesthetic medicine in recent years. It is used primarily in rejuvenating the skin of the face, neck and cleavage and in body fat reduction. The ultrasound waves release a large amount of energy, increasing the temperature in the surrounding tissues, contributing to neocollagenesis and tissue remodelling and reducing the size of adipocytes in the adipose tissue. The results of current scientific reports seem to be promising. In the literature, we find articles on the use of the HIFU method in new indications. HIFU treatments, despite being minimally invasive, may be accompanied by complications. The following review analyses the use of the HIFU method, its effects and complications.</p>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 3","pages":"e120-e125"},"PeriodicalIF":2.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Therapies for Slow-Flow Vascular Malformations","authors":"Grace X. Li,&nbsp;Deshan F. Sebaratnam,&nbsp;James P. Pham","doi":"10.1111/ajd.14451","DOIUrl":"10.1111/ajd.14451","url":null,"abstract":"<p>Advances in genetic sequencing technologies have enabled the identification of key activating somatic variants in cellular signalling pathways involved in the pathogenesis of vascular malformations. Given that these genetic variants are also implicated in the pathogenesis of several cancers, the repurposing of targeted therapies developed in oncology has been increasingly investigated for treating vascular malformations. This review provides an update on the current evidence for targeted therapies in slow-flow vascular malformations, particularly in the context of gain-of-function variants in the <i>PI3K/AKT/mTOR</i> pathway.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 3","pages":"142-151"},"PeriodicalIF":2.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14451","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Similar Molecular Features in Two Cases of CARD14-Associated Papulosquamous Eruption","authors":"Yumeng Wang,&nbsp;Bing Wang,&nbsp;Jiawen Chen,&nbsp;Fuh-Miin Liang,&nbsp;Haifei Liu,&nbsp;Jinxiang Yang,&nbsp;Ming Li,&nbsp;Zhirong Yao,&nbsp;Xiaobo Feng","doi":"10.1111/ajd.14455","DOIUrl":"10.1111/ajd.14455","url":null,"abstract":"<div>\u0000 \u0000 <p>Subjects carrying variants in the caspase recruitment domain family member 14 (<i>CARD14</i>) gene can exhibit characteristics of psoriasis and pityriasis rubra pilaris (PRP). The term ‘CARD14-associated papulosquamous eruption (CAPE)’ is used to describe individuals presenting with symptoms of both conditions. This study aimed to diagnose two cases of CAPE and explore the pathogenic mechanisms, including inflammatory trends and differential features. Whole-exome sequencing and Sanger sequencing identified a novel variant, c.2768T&gt;C and a recurrent variant, c.467T&gt;C, in <i>CARD14</i> in two unrelated individuals, both exhibiting incomplete penetrance. Both of patients exhibited increased IL-17A in skin lesions, but not in serum, potentially explaining the reported cases with low response rate to secukinumab. One patient also exhibited increased IL-23A in serum. Additionally, the epidermis of lesions showed aberrant late differentiation and active NF-κB signalling.</p>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 3","pages":"e171-e175"},"PeriodicalIF":2.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erosive Lichen Planus Treated With Tofacitinib: A Case Series of 23 Patients","authors":"Vera Y. Miao,&nbsp;Miranda K. Branyiczky,&nbsp;Rebecca B. Saunderson,&nbsp;Gayle Fischer","doi":"10.1111/ajd.14452","DOIUrl":"10.1111/ajd.14452","url":null,"abstract":"&lt;p&gt;Dear Editor,&lt;/p&gt;&lt;p&gt;Erosive lichen planus (ELP) is a chronic inflammatory dermatosis manifesting as painful erosions and ulcers that can affect the oral, anogenital, oesophageal, and other mucosal sites. Erosive vulvovaginal lichen planus (EVLP) causes chronic symptoms and scarring, which lead to significantly diminished sexual function and quality of life (QoL) [&lt;span&gt;1&lt;/span&gt;]. EVLP may be very difficult to treat, with up to 40% of cases not responding to first-line topical corticosteroid therapy and requiring systemic agents [&lt;span&gt;2&lt;/span&gt;]. The varying efficacy and side effect profiles of traditional immunosuppressive agents such as prednisolone, methotrexate, mycophenolate mofetil, azathioprine, cyclosporine, and hydroxychloroquine highlight the need for more targeted therapies. Several molecular and clinical studies have evidenced the Janus kinase-signal transducer and activator of transcription (JAK–STAT) pathway as playing a crucial role in ELP pathogenesis [&lt;span&gt;3&lt;/span&gt;]. Tofacitinib, a second-generation inhibitor of JAK1 and JAK3, has demonstrated promising responses in case reports of patients with ELP [&lt;span&gt;4-7&lt;/span&gt;]. We aimed to determine whether tofacitinib can confer a favourable response in a larger patient group and present this case series.&lt;/p&gt;&lt;p&gt;Twenty-three adult women with EVLP, including six with concurrent refractory oral ELP and one with oral and oesophageal ELP, treated with oral tofacitinib 5 mg twice daily, were identified from the patient database of a vulvovaginal sub-specialty clinic. The mean age at diagnosis was 48.4 (range 20–69) years and the mean follow-up duration was 5.7 (range 2–9) years. In keeping with previously published data, histopathology is unreliable, and only 10 women had biopsy features suggestive of EVLP [&lt;span&gt;8&lt;/span&gt;]. The remaining 13 women met previously described diagnostic criteria [&lt;span&gt;8, 9&lt;/span&gt;]. The mean duration of disease before commencement of tofacitinib was 9.1 (range 3–34) years, during which various topical and systemic therapies were trialled with limited efficacy (Table 1).&lt;/p&gt;&lt;p&gt;Due to a lack of validated scoring systems for disease severity, treatment response was assessed by clinical and symptomatic improvement. Two clinicians (a dermatologist experienced in vulval dermatology (R.B.S.) and a vulval dermatology research fellow (V.Y.M.)) assessed the disease severity of EVLP using photographs taken before commencing and at the latest follow-up after tofacitinib using a physicians' global assessment (PGA) five-point scale (Figures 1 and 2). 13.0% (&lt;i&gt;n&lt;/i&gt; = 3/23) improved by two severity categories, 52.2% (&lt;i&gt;n&lt;/i&gt; = 12/23) improved by one category, and the remaining 34.8% (&lt;i&gt;n&lt;/i&gt; = 8/23) did not change in PGA severity although reported symptomatic improvement. The average time to symptomatic improvement of vulvovaginal disease was 3.7 (range 1–8) months. All seven women with concurrent oral/oesophageal ELP achieved a complete response of their oral/oesophageal di","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 4","pages":"234-237"},"PeriodicalIF":2.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14452","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics, Management and Long-Term Outcomes of 180 Patients With Early-Stage Mycosis Fungoides at a Tertiary Centre—A 34-Year Retrospective Study","authors":"Banu Ismail Mendi,&nbsp;Incilay Kalay Yıldızhan,&nbsp;Hatice Şanlı","doi":"10.1111/ajd.14449","DOIUrl":"10.1111/ajd.14449","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mycosis fungoides (MF) is the commonest form of primary cutaneous T-cell lymphoma. Progression is slow, with frequent relapses. Data for predicting early-stage MF progression and recurrence are inadequate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The clinical profile, treatment response, relapse, progression to advanced stage and final status of 180 patients diagnosed with early MF between <i>January 1987 and September 2021</i> were investigated retrospectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ninety-four (52.2%) patients were female and 86 (47.8%) male. Stage at diagnosis was IA in 74 (41.1%) patients, IB in 72 (40%) and IIA in 34 (18.9%). Initial treatment was PUVA in 76 (42.2%) patients and NB–UVB in 59 (32.7%). Complete response occurred in 109 (60.5%) patients, and 73 (51.5%) patients experienced recurrence. Stage IA/IB at diagnosis, normal B-2-microglobulin levels and low CLIPI score were associated with complete response. Progression to advanced stage occurred in 27 (%15) patients. Age 60 and over at diagnosis, stage at diagnosis, pruritus, LDH, CLIPI score between 3 and 5, and folliculotropism in pathology were found to be negative prognostic factors in progression to advanced stage. Classical pathology, PUVA treatment and complete response to initial treatment were found to be positive prognostic factors. In multivariate analysis, LDH and complete responsiveness to initial treatment were independently associated with progression to advanced stage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Advanced age at diagnosis, a high CLIPI score and folliculotropism affect both progression to advanced stage and the final status of the disease. LDH level is a crucial indicator of progression to an advanced stage. Early diagnosis affects the treatment response, with a complete response to the initial treatment mitigating the risk of advanced-stage progression.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 3","pages":"e126-e139"},"PeriodicalIF":2.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NZDSI Conference 2024","authors":"","doi":"10.1111/ajd.14440","DOIUrl":"10.1111/ajd.14440","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 2","pages":"e67-e79"},"PeriodicalIF":2.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}